A strong method for identifying extremely small amounts of antigens is immuno-PCR (iPCR). It combines the benefits of PCR and ELISA in terms of specificity, sensitivity, and simplicity of adaptation. Despite its potential, iPCR is a technology that is underutilized, as shown by the lack of validated, ready-to-use commercial kits and the small number of publications on its routine implementation.
Novatein Biosciences is introducing validated and ready-to-use iPCR conversion kit (cat# NB-iPCR42) and iPCR kits to enable researchers to identify various low-abundant analytes.

For details visit - https://novateinbio.com/content/64-ultrasensitive-elisa-and-immunopcr